Maxwell Biosciences

Today is Scientist Appreciation Day at Maxwell Biosciences. We started this as an internal company holiday to celebrate the people behind the breakthroughs that fuel our world. This year, we’re inviting you to join in. If you’re a scientist—working in a lab, teaching in a classroom, out in the field, or between jobs—we want to hear from you. Share your story. Share your work. We see you. 💡 For the rest of us: ➡️ Tag a scientist you admire (don’t forget: #WeAppreciateScientists) ➡️ Post a public thank-you ➡️ Support science—fund it, cite it, amplify it Read more about how we’re celebrating: https://lnkd.in/ezpfTjQT #WeAppreciateScientists #ScientistAppreciationDay #MaxwellBiosciences

With immense gratitude and excitement, Maxwell is proud to share we’ve closed our $20M financing round. As we prepare for FDA clinical trials and begin commercializing nonclinical Claromer™-based products, strong financial backing lets us move aggressively without hesitation. This raise allows us to: ▹ Prepare for clinical trials on schedule ▹ Scale manufacturing and regulatory frameworks ▹ Expand partnerships and commercial channels Read more here: https://lnkd.in/exFaN8ND

Maxwell is expanding its AI-first approach with the launch of a formal AI division focused on accelerating drug discovery and the development of AI-powered medical devices. As part of this initiative, Jon McClure has been named CTO to lead the company’s AI engineering strategy. “The future of medicine requires scalable intelligence, and Jon brings exactly that—combined with deeply human values,” said CEO, Founder & Chairman Joshua McClure. “Our AI division will serve as both accelerator and amplifier—driving faster drug design, analyzing clinical trial data and infusing every part of Maxwell with AI.” AI has been central to Maxwell’s work since its founding in 2016—designing molecules, modeling biology and streamlining operations in real time. This new division deepens that commitment, supporting scalable innovation across all areas of the business. 📍 Read the full announcement: https://lnkd.in/eCY5mG3D #MaxwellBiosciences #AI #DrugDiscovery #HealthTech #Claromers #CTO #BiotechLeadership #AIDivision

Join Maxwell Biosciences at Aging Research & Drug Discovery Meeting 2025—the premier global meeting for aging research and drug discovery. Our COO & Head of R&D Edward M. Rudnic, Ph.D. will present a keynote entitled: “Longevity Peptides, the Microbiome and the Gut-Brain Axis” This session will explore how immune-inspired peptide mimics may unlock new interventions at the intersection of microbial health, neurological function and longevity. For leaders in peptide innovation, neurobiology or microbiome science—this is one to watch. #Longevity #AgingResearch #GutBrainAxis #Microbiome #MaxwellBiosciences #ARDD2025 #DrugDiscovery #TranslationalScience August 25–29 | University of Copenhagen & Virtual Learn more at https://agingpharma.org

📢 Reminder: Join us at the 12th Annual Aging Research & Drug Discovery Meeting (ARDD 2025) from August 25-29 at the University of Copenhagen’s Ceremonial Hall or online. Our COO and Head of R&D, Edward M. Rudnic, Ph.D. will be speaking at this premier longevity conference, alongside global leaders like Nobel laureates Morten Meldal and Michael Levitt. Don’t miss the latest advancements in aging research and drug discovery. Secure your spot for virtual or in-person attendance at agingpharma.org. #ARDD2025 #AgingResearch #Longevity #MaxwellBiosciences

Today, Maxwell Biosciences announces strategic partnerships and licensing in cosmetics and personal care with our immune-inspired Claromer™ platform. Claromers™ are immune-inspired molecules designed to support the skin microbiome while providing broad-spectrum protection. -- Engineered for stability and safety -- Effective against bacteria, fungi, viruses and biofilms -- Compatible with the needs of modern skincare innovators We’re enabling a new era of microbiome-safe, science-backed personal care. 📣 Learn more and watch our announcement video: 🔗 https://lnkd.in/eb4TcjUZ #CosmeticsInnovation #MicrobiomeSafe #Licensing #Claromers #MaxwellBiosciences

Thanks for the shoutout, The Defense Post!

Diarrheal disease remains the #1 infectious threat to U.S. troop readiness. Drug-resistant pathogens are outpacing conventional antibiotics, threatening both mission performance and long-term health. Today, we’re proud to announce a new Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the U.S. Naval Medical Research Command’s DAID lab to evaluate our Claromer™ compounds as a next-generation solution. Here's the highlights: 🔹 7th U.S. military collaboration 🔹 Claromers™ = synthetic small molecules mimicking innate immune system 🔹 Broad-spectrum efficacy against bacteria, viruses, fungi and biofilms 🔹 Stable, scalable and engineered for extreme environments This partnership further validates Claromers™ as a mission-ready innovation uniquely positioned to defend against one of the military’s most pervasive threats. 📍 Learn more at: https://lnkd.in/eQ3JtMk7 #DefenseInnovation #BiotechLeadership #CombatReadiness #AntimicrobialResistance #DrugDiscovery #MaxwellBiosciences #OneDrugManyBugs #MilitaryHealth

Discover how Maxwell Biosciences is advancing biodefense with its Claromer™ platform in an exclusive Contract Pharma interview. CEO Joshua McClure discusses U.S. Military partnerships, a $3M MTEC award and innovative therapeutics for infectious diseases like Dengue Fever. Read the full story to explore Maxwell's vision for global health security: https://lnkd.in/egAyNsDE

ICYMI: Maxwell Biosciences CEO on Claromers™ and the Future of Longevity In a recent Lifespan.io Longevity News interview, Maxwell CEO Joshua McClure dives into how Claromers™—synthetic small molecules mimicking the immune peptide LL-37—could transform healthspan by combating infectious disease. From nonhuman primate trials to collaborations with the US military and India, McClure outlines a bold vision: eradicating infections as the primary driver of aging. Read the full interview here: https://lnkd.in/e8GJr-yA